SGLT-2 INHIBITION IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IS A KEY PRINCIPLE IN CARDIOPROTECTION AND NEPHROPROTECTION
N. Kostadinov, D. Stoyanova, B. Mirazchiiski, V. Gonchev
Pages: 6-9
ABSTRACT: The high prevalence of diabetes mellitus, the high cost of its treatment, including complications, determine the need to seek new approaches and methods of prevention diagnosis and treatment of diabetes mellitus and its complications The spread of diabetes is
pandemic. Every year the number of diabetics increases by 6 million, the forecast is that by
2025 they will reach over 300 million. Bulgaria ranks 6th in the prevalence of diabetes with an
impressive 7% of the population. According to a report by the European Commission and the
EU's Economic Policy Committee, the disease of the highest economic severity is obesity,
followed by diabetes. Undoubtedly, this priority is due to a number of complications directly
related to the so-called metabolic syndrome and the development of peripheral
neurodegenerative disorders and vascular degenerative changes with effects on the retina,
heart, kidneys and lower extremities. These complications most often lead to severe disability,
permanent incapacity for work, social incapacity and inadequacy, deterioration of the overall
quality of life of patients and their families. In this context, we consider the role of SGLT-2i as
a fulcrum in the treatment of type 2 diabetes given the additional protection they provide.
Keywords: diabetes mellitus, diagnosis, treatment, SGLT-2 inhibitors (SGLT2i), diabetic
nephropathy, diabetic macroangiopathy
